Neumora Therapeutics

Neumora Therapeutics

  • Founded: 2020
  • Location: Watertown, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Depression
  • Drug types: NEU, PSY
  • Lead product: NMRA-140
  • Product link:
  • Funding: $112M B Oct 2022; $500M A Oct 2021
  • Investors: Abu Dhabi Growth Fund (ADG), Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners

job board

Short description:

Precision Medicines for Brain Diseases

Drug notes:

NMRA-511 Clin1 anxiety; NMRA-M4R Clin0 neuropsychiatric disorders; NMRA-GRIN2A Clin0 neuropsychiatric disorders; 3 programs RD/Clin0 neurodegenerative diseases

Long description:

Neumora Therapeutics is a biopharmaceutical company founded to address the global brain disease crisis and improve patient lives through the development of targeted and effective neurodegenerative and neuropsychiatric therapies. Neumora’s therapeutics are aimed to target relevant pathways across various CNS diseases. They also leverage a precision medicine approach to identify patient populations of interest. Their research investigates the mechanisms of action behind major depressive disorder, schizophrenia, bipolar depression, Alzheimer’s, ALS, and Parkinson’s disease. Utilizing their precision medicine approach, Neumora is committed to discovering novel therapeutic targets and developing effective and meaningful therapies.


Neumora Therapeutics
Director, Clinical Quality Assurance (cQA)
Stati Uniti d'America|4 days ago
Neumora Therapeutics
Vice President, Clinical Quality Assurance
Stati Uniti d'America|10 days ago
Neumora Therapeutics
Senior Medical Director-Neuropsychiatry
Stati Uniti d'America|17 days ago
Neumora Therapeutics
Director, Product Quality(Pharma/Biotech)
Stati Uniti d'America|26 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy